Research programme: mTOR protein inhibitors - Pfizer

Drug Profile

Research programme: mTOR protein inhibitors - Pfizer

Alternative Names: WYE-125132

Latest Information Update: 06 Sep 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Pyrazoles; Pyrimidines
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 01 Sep 2011 Early research is ongoing in US
  • 15 Oct 2009 Wyeth has been acquired by Pfizer
  • 20 Aug 2009 Initial pharmacodynamics data from a preclinical study in Cancer presented at the 238th-American Chemical Society National Meeting (238th-ACS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top